Search & Filter

2 articles

Opinion: FDA commissioner nominee Heidi Overton is ignoring the science on abortion drug

Heidi Overton, nominee for commissioner of the Food and Drug Administration, avoided directly addressing her views on mifepristone during a Senate health committee meeting. As CEO of Reproductive Futures, a legal organization advocating for reproductive rights, the author expresses concern that Overton's anti-abortion views could lead to harmful policies if she becomes FDA commissioner.

Read →
Julie F. Kay|STAT News|